| Literature DB >> 34087874 |
Shigeta Miyake1,2, Takuma Higurashi1,3, Takashi Jono1,4, Taisuke Akimoto1,2, Fumihiro Ogawa1,5, Yasufumi Oi1,5, Katsushi Tanaka1,6, Yu Hara1,6, Nobuaki Kobayashi1,6, Hideaki Kato1,7, Tsuneo Yamashiro8, Daisuke Utsunomiya8, Atsushi Nakajima1,3, Tetsuya Yamamoto1,2, Shin Maeda1,9, Takeshi Kaneko1,6, Ichiro Takeuchi1,5.
Abstract
ABSTRACT: The Coronavirus disease 2019 pandemic continues to spread worldwide. Because of the absence of reliable rapid diagnostic systems, patients with symptoms of Coronavirus disease 2019 are treated as suspected of the disease. Use of computed tomography findings in Coronavirus disease 2019 are expected to be a reasonable method for triaging patients, and computed tomography-first triage strategies have been proposed. However, clinical evaluation of a computed tomography-first triage protocol is lacking.The aim of this study is to investigate the real-world efficacy and limitations of a computed tomography-first triage strategy in patients with suspected Coronavirus disease 2019.This was a single-center cohort study evaluating outpatients with fever who received medical examination at Yokohama City University Hospital, prospectively registered between 9 February and 5 May 2020. We treated according to the computed tomography-first triage protocol. The primary outcome was efficacy of the computed tomography-first triage protocol for patients with fever in an outpatient clinic. Efficacy of the computed tomography-first triage protocol for outpatients with fever was evaluated using sensitivity, specificity, positive predictive value, and negative predictive value. We conducted additional analyses of the isolation time of feverish outpatients and final diagnoses.In total, 108 consecutive outpatients with fever were examined at our hospital. Using the computed tomography-first triage protocol, 48 (44.9%) patients were classified as suspected Coronavirus disease 2019. Nine patients (18.8%) in this group were positive for severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction; no patients in the group considered less likely to have Coronavirus disease 2019 tested positive for the virus. The protocol significantly shortened the duration of isolation for the not-suspected versus the suspected group (70.5 vs 1037.0 minutes, P < .001).Our computed tomography-first triage protocol was acceptable for screening patients with suspected Coronavirus disease 2019. This protocol will be helpful for appropriate triage, especially in areas where polymerase chain reaction is inadequate.Entities:
Mesh:
Year: 2021 PMID: 34087874 PMCID: PMC8183760 DOI: 10.1097/MD.0000000000026161
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Representative features of chest computed tomography (CT) classifications. Chest CT scans of outpatients with fever. CT features classified into 5 categories according to the COVID-19 Reporting and Data System (CO-RADS). (A) CO-RADS 1, normal CT or non-infectious etiology (e.g., lung tumor, lung fibrosis). (B) CO-RADS 2, infectious etiology that is not compatible with COVID-19 (e.g., infectious bronchiolitis, bronchopneumonia, lobar pneumonia). (C) CO-RADS 3, equivocal findings for COVID-19 (e.g., homogeneous extensive ground-glass opacities [arrow]). (D) CO-RADS 4, typical CT findings of COVID-19 (similar to CO-RADS 5) but showing some overlap with other pneumonia. (E) CO-RADS 5, typical CT findings of COVID-19 (e.g., multifocal ground-glass opacities with or without consolidation in lung regions close to visceral pleural surfaces).
Characteristics of outpatients with fever.
| Characteristics | N = 108 | |
| Age, yr (mean ± SD, range) | 58.9 ± 19.5 | Range: 18–101 |
| Sex | ||
| Male | 60 | 55.6% |
| Female | 48 | 44.4% |
| Clinical history | ||
| Overseas travel history | 4 | 3.7% |
| Contact with a COVID-19 case | 8 | 7.4% |
| Comorbidity | ||
| Any | 74 | 68.5% |
| Chronic pulmonary disease | 21 | 19.4% |
| Diabetes | 14 | 13.0% |
| Hypertension | 25 | 23.1% |
| Chronic renal failure | 6 | 5.6% |
| Cardiovascular disease | 10 | 9.3% |
| Cerebrovascular disease | 4 | 3.7% |
| Malignancy | 20 | 18.5% |
| Symptoms | ||
| Fever | 77 | 71.2% |
| Respiratory symptoms | 55 | 50.9% |
| Fatigue | 37 | 34.3% |
| Headache | 20 | 18.5% |
| Taste or olfactory disorder | 7 | 6.5% |
Figure 2Computed tomography (CT)-first triage protocol for outpatients with fever and participant flow. Overview of the CT-first triage protocol for outpatients with fever and participant flow. Yellow area indicates duration of isolation, requiring personal protective equipment (PPE). One patient was excluded from the CT-first triage protocol because of pregnancy; the remainder were triaged using the protocol. Patients in the group less likely to have Coronavirus disease 2019 (COVID-19), classified according to the COVID-19 Reporting and Data System (CO-RADS) and the patient's clinical history, were treated using normal equipment and were finally diagnosed after further examination. The “COVID-19 less likely” group was followed for 14 days after visiting our outpatient clinic. The suspected COVID-19 group was tested using polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with negative PCR test results for SARS-Co-2 were treated using normal equipment and were finally diagnosed after further examination.
Results of CT-first protocol.
| COVID-19 suspected (n = 48) | COVID-19 less likely (n = 59) | ||||
| Patients | 48 | 44.9% | 59 | 55.1% | |
| Age, yr (mean ± SD, range) | 61.1 ± 17.8 | Range: 21–90 | 57.3 ± 20.9 | Range: 18–101 | |
| Sex (number, %) | |||||
| Male | 27 | 56.3% | 33 | 55.9% | |
| Female | 21 | 43.8% | 26 | 44.1% | |
| CT feature | |||||
| CO-RADS (number, %) | |||||
| Category 1 | 6 | 12.5% | 42 | 71.2% | |
| Category 2 | 9 | 18.8% | 17 | 28.8% | |
| Category 3 | 14 | 29.2% | 0 | 0.0% | |
| Category 4 | 6 | 12.5% | 0 | 0.0% | |
| Category 5 | 13 | 27.1% | 0 | 0.0% | |
| Duration of isolation | |||||
| Time until CT confirmation, min (mean ± SD, range) | 81.7 ± 48.8 | Range: 23–289 | 70.5 ± 41.2 | Range: 19–297 | |
| Time until PCR confirmation, min (mean ± SD, range) | 1013 ± 505.5 | Range: 255–1665 | |||
| Isolation duration, non-COVID-19 group, min (mean ± SD, range) | 1037.0 ± 512 | Range: 255–1665 | 70.5 ± 41.2 | Range: 19–297 | |
Clinical outcomes.
| COVID-19 suspected (n = 48) | COVID-19 less likely (n = 59) | |||
| Final diagnosis | ||||
| COVID-19 | 9 | 18.8% | 0 | 0.0% |
| Not COVID-19 | 39 | 81.2% | 59 | 100% |
| Respiratory infection | 23 | 47.9% | 28 | 47.5% |
| Other focal infection (meningitis) | 7 (2) | 14.6% (4.2%) | 15 (2) | 25.4% (3.4%) |
| Interstitial pneumoniae | 4 | 8.3% | 0 | 0.0% |
| Tumor-related fever | 2 | 4.2% | 3 | 5.1% |
| Collagen disease | 0 | 0.0% | 2 | 3.4% |
| Acute myocardial infarction | 0 | 0.0% | 1 | 1.7% |
| Others | 3 | 6.3% | 10 | 16.9% |
| Clinical outcome | ||||
| Death | 1 | 2.1% | 1 | 1.7% |
| Hospitalization | 31 | 64.6% | 20 | 33.9% |
| Not hospitalized | 17 | 35.4% | 39 | 66.1% |